TECZEM
LOE Approachingdiltiazem malate; enalapril maleate
NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECZEM is a fixed-dose combination tablet containing diltiazem malate (a calcium channel blocker) and enalapril maleate (an ACE inhibitor) in extended-release formulation. It is indicated for hypertension management in patients requiring dual antihypertensive therapy. The combination provides synergistic blood pressure reduction through two complementary mechanisms of action.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential contraction in brand team size and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TECZEM offers limited career growth opportunity due to its LOE-approaching status and minimal linked job openings (0 recorded). Roles available focus on defensive strategies, market retention, and preparation for generic competition rather than expansion or innovation.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.